

Contents

Introduction

1

Trends in Deal Making

- 1.1 Recent trends
- 1.2 Deal Making by the top 25 Pharmaceutical Companies
- 1.3 Biotechnology Company Perspective
- 1.4 Sector Trends
- 1.5 Changing Deals for Difficult Economic Times

2

Valuation Methods

- 2.1 Combining Methods
- 2.2 Why use eNPV and Benchmarking
 - 2.2.1 Benchmarking
 - 2.2.2 Expected Net Present Value
 - 2.2.3 Decision trees
 - 2.2.4 Sensitivity Analysis
 - 2.2.5 Value Sharing

3

Simple Licensing Agreements

- 3.1 Simple License Definition
 - 3.1.1 Rationale
 - 3.1.2 PharmaDeals Analysis
- 3.2 Key Issues
 - 3.2.1 Simple License
- 3.3 Case Study

4

R&D Collaboration Agreements

- 4.1 Rationale
- 4.2 PharmaDeals Analysis
- 4.3 Case Study

5

Evaluation Agreements

- 5.1 Rationale
- 5.2 PharmaDeals Analysis
- 5.3 Case Study

6

Technology Access Agreements

- 6.1 Rationale
- 6.2 PharmaDeals Analysis
- 6.3 Case Study

7

Co-Marketing & Co-Promotion Agreements

- 7.1 Rationale
- 7.2 PharmaDeals Analysis
- 7.3 Key Issues
- 7.4 Case Study

8

Marketing Agreements

- 8.1 Rationale
- 8.2 PharmaDeals Analysis
- 8.3 Case Study

9

Product Sale and Purchase Agreements

- 9.1 Single Product Sale/Purchase
 - 9.1.1 Rationale
- 9.2 PharmaDeals Analysis
- 9.3 Case Study

10

Option Agreements

- 10.1 Option to Purchase
 - 10.1.1 Rationale
- 10.2 PharmaDeals Analysis
- 10.3 Option to License
 - 10.3.1 Rationale
- 10.4 PharmaDeals Analysis
- 10.5 Key Issues
 - 10.5.1 License with Option to Purchase
- 10.6 Valuation Models
 - 10.6.1 License with Option to Purchase
- 10.7 Case Study

11

Equity Investments

12

Alternate Deal Structures

12.1 Drug Royalty Companies

12.2 Risk Sharing Agreements with Contract research Organisations

12.2.1 Case Study

12.3 Quids

12.3.1 Rationale

12.3.2 PharmaDeals analysis

Figures

- 1 All Deals by Year
- 2 Product deals breakdown
- 3 Total deal values
- 4 Top 25 Pharmaceutical Companies: Deals versus Sales
- 5 Deal Intensity of the Top 10 Pharmaceutical Companies
- 6 Deal Intensity by Therapeutic Area
- 7 Deals by Territory
- 8 Hypothetical Deal Factors
- 9 Pharmaceutical Product Decision Tree.
- 10 Approximate Deal Value Splits by Development Phase
- 11 All Simple Licensing Deals By Year
- 12 Deal Values by Year
- 13 Licensing Deals By Development Phase and Year
- 14 Licensing Deals by Technology
- 15 Territorial Distribution of Licensing Deals
- 16 Simple Licensing Deals by Therapeutic Area
- 17 R&D Collaboration Deals
- 18 Collaborative R&D Deals By Development Phase
- 19 Collaborative R&D Deals by Technology
- 20 Co-development Deals by Territory
- 21 Collaborative R&D Deal Values
- 22 Evaluation Agreements by Year
- 23 Evaluation Agreements by Development Phase
- 24 Evaluation Agreements by Technology
- 25 Evaluation Agreements by Territory
- 26 Evaluation Agreements by Value
- 27 Evaluation Agreements by Therapeutic Area
- 28 Technology Access Agreements by Year
- 29 Technology Access Agreements By Development Phase
- 30 Technology Access Agreements by Technology
- 31 Technology Access Agreements by Territory
- 32 Technology Access Agreements by Deal Value
- 33 Technology Access Agreements by Therapeutic Area
- 34 Total Co-Marketing & Co-Promotion Deals By Year
- 35 Co-Marketing & Co-Promotion Deals by Development Phase
- 36 Co-Marketing & Co-Promotion Deals by Technology
- 37 Co-Marketing & Co-Promotion Deals by Territory
- 38 Co-Marketing & Co-Promotion Deal Values
- 39 Marketing Agreements by Year
- 40 Marketing Agreements by Development Phase
- 41 Marketing Agreements by Technology
- 42 Marketing Agreements by Territory
- 43 Marketing Agreements Total Deal Value
- 44 Marketing Agreements by Therapeutic Area
- 45 Product Acquisitions by Year
- 46 Product Acquisitions by Development Phase
- 47 Product Acquisitions by Technology
- 48 Product Acquisition by Territory
- 49 Product Acquisition Total Deal Values
- 50 Product Acquisition by Therapeutic Area
- 51 Option to Purchase Deals by Year
- 52 Option to Purchase Deal Values
- 53 Option to Purchase Deals by Development Phase
- 54 Option to Purchase Deals by Technology
- 55 Option to Purchase Deals by Territory
- 56 Option to Purchase Deals by Therapeutic Area
- 57 Option to License Deals by Year
- 58 Option to License Deals by Development Phase
- 59 Option to License Deals By Technology
- 60 Option to License Deals by Territory
- 61 Option to License Deal Values
- 62 Option To License Deals By Therapeutic Area
- 63 Equity Investments – All Deals
- 64 Equity Investments by Development Phase
- 65 Equity Investment Deals by Technology
- 66 Equity Investment Deals by Territory
- 67 Equity Investments – Total Deal Values
- 68 Equity Investment Deals by Therapeutic Area